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Summary To provide advice on the rational use of antimalarial drugs, Me ´decins Sans Frontie `res conducted a
randomized, an open label efﬁcacy study in Kajo Keji, an area of high transmission of malaria in
southern Sudan. The efﬁcacy of chloroquine (CQ), sulphadoxine–pyrimethamine (SP) and amodiaquine
(AQ) were measured in a 28-day in vivo study, with results corrected by PCR genotyping. Of 2010
children screened, 115 children aged 6–59 months with uncomplicated Plasmodium falciparum malaria
were randomized into each group to receive a supervised course of treatment. Of these, 114, 103 and
111 were analysed in the CQ, SP and AQ groups, respectively. The overall parasitological failure rates at
day 28 were 93.9% [95% conﬁdence interval (CI) 87.3–97.3] for CQ, 69.9% (95% CI 60.0–78.3) for
SP, and 25.2% (95% CI 17.7–34.5) for AQ. These results provide important missing data on
antimalarial drug efﬁcacy in southern Sudan. They indicate that none of the drugs could be used in
monotherapy and suggest that even in combination with artemisinin, cure rates might not be efﬁcacious
enough. We recommend a combination of artemether and lumefantrine as ﬁrst-line treatment for
uncomplicated P. falciparum malaria cases in Kajo Keji county.
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Introduction
Apart from a 10-year period of relative peace from 1972 to
1983, Sudan has been divided by civil war for nearly half a
century. The long-lasting war left the southern part of the
country in administrative, economic, political and social
decay. In this state of complex emergency, malaria, the
leading health problem in Sudan, is inadequately con-
trolled (WHO 2000). It is estimated that in the southern
sector of Sudan, 24–36% of the population are affected
with malaria (UN/OCHA 2002).
In Kajo Keji County, in the south of Sudan where
Me ´decins Sans Frontie `res (MSF) supports Mundari Hos-
pital, malaria accounts for 32% of the total consultations,
51% of the under ﬁve children consultations and 26% of
hospital deaths (MSF, unpublished data). The ﬁrst-line
treatment of uncomplicated Plasmodium falciparum mal-
aria was chloroquine (CQ) with sulphadoxine–pyrimeth-
amine (SP) as second and quinine as third-line treatment.
Verbal accounts from the local clinicians suggested that
CQ and SP were losing their efﬁcacy, however no recent
information concerning resistance to these drugs was
available. Moreover, there are only limited data on the
current efﬁcacy of antimalarial drugs in other parts of
south Sudan (van den Broek et al. 2003). To ﬁll this data
gap and explore possible alternatives to the ﬁrst-line
treatment used in this site, we decided to conduct an in vivo
efﬁcacy study of CQ, SP, and amodiaquine (AQ) among
children under the age of 5 in Kajo Keji.
Methods
Study site and duration
The study was conducted in a separate clinic of Mundari
Hospital, where MSF has been working since 1997. It is the
referral hospital of Kajo Keji County (150 000 inhabit-
ants), situated in western Equatoria near the border with
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during the rainy seasons of May–August and January/
February. Ethical approval for the study was obtained from
the Sudan Relief and Rehabilitation Association (SRRA)
authorities.
Patients, study procedures and treatment
The study protocol was based on the 1996 WHO guide-
lines (WHO 1996). Patients with fever (axillary tempera-
ture ‡37.5  C) or history of fever in the past 24 h were
screened at the hospital outpatients department and
referred to the laboratory and then to the study clinic.
Children aged 6–59 months with P. falciparum mono-
infection and asexual parasitaemia of 1000–100 000/ll
were eligible for the study. They were excluded if at least
one of the following criteria was present: (i) signs of severe
malaria (WHO 1996); (ii) severe malnutrition (weight-for-
height <70% of the median or bilateral oedema); (iii)
severe infectious disease; (iv) history of hypersensitivity
reactions to the drugs under evaluation; (v) intake of a
complete treatment of CQ, SP or AQ within the previous
3 days; or (vi) residence at more of 10 km from the
hospital. Written, informed consent was obtained by
signature or ﬁngerprint from parents or guardians. Patients
were randomly allocated to one of the three treatment
groups: (i) CQ base tablet of 150 mg (Avloclor , ZEN-
ECA, at a dose of 25 mg/kg base divided over 3 days); (ii)
sulphadoxine 500 mg + pyrimethamine 25 mg (Fansi-
dar , Roche, as a single dose of 1.25 mg/kg); (iii)
amodiaquine hydrochloride base tablet of 200 mg (Cam-
oquine, Parke-Davis, France, at a dose of 30 mg/kg base
divided over 3 days). Allocation followed a block rand-
omization procedure (blocks of 10). Treatments were kept
in sealed envelopes that were opened at the end of the
inclusion procedure, when the child received the treatment.
All doses were directly observed by the study clinician; the
complete dose was repeated in case of vomiting within
30 min, while half the dose was repeated in case of
vomiting after 30–60 min.
Follow-up visits with clinical and parasitological exam-
inations were scheduled on days 1, 2, 3, 7, 14, 21 and 28.
Haemoglobin was measured at day 0. Samples for PCR
genotyping were taken at entry and in case of treatment
failure after day 10 of follow-up. Rescue therapy for
patients failing treatment with AQ or CQ was SP, while
patients failing treatment on SP were treated with quinine.
Children were secondarily withdrawn from the study in
case of: (i) allergic reaction to the study drug; (ii)
movement of the patient outside the study site; (iii)
withdrawal of consent; (iv) intake of drugs with antima-
larial activity; (v) detection of mixed malaria infection
during days 2 or 3; (vi) vomiting of any of the antimalarial
drug more than twice; (vii) occurrence of a concomitant
disease that would interfere with the classiﬁcation of the
outcome. Patients who missed follow-up visits and did not
come on successive days despite tracing were considered
lost to follow-up.
Therapeutic outcomes
Therapeutic outcomes were determined according to par-
asitological and clinical observations made during follow-
up. Early treatment failure (ETF) was deﬁned in case of: (i)
severe malaria on days 1, 2 or 3 in the presence of
parasitaemia, or (ii) axillary temperature ‡37.5  C on day
2 with parasitaemia greater than that of day 0, or (iii)
axillary temperature ‡37.5  C on day 3 with parasitaemia,
or (iv) parasitaemia on day 3 > 25% of that of day 0. Late
treatment failure (LTF) was deﬁned in case of: (i) devel-
opment of danger signs or signs of severe malaria after day
3 in the presence of parasitaemia without previously
meeting any of the criteria of ETF, or (ii) presence of
parasitaemia on any day after day 3 without previously
meeting any of the criteria of ETF. Absence of ETF and
LTF deﬁned an adequate treatment response (ATR). After
PCR genotyping, reinfections were reclassiﬁed as ATR and
recrudescences were reclassiﬁed as LTF. When the PCR
was non-available, the case was excluded from the
analysis.
Laboratory methods
Capillary blood was obtained by ﬁngerprick. Thick blood
ﬁlms were stained with 10% Giemsa for 20 min. Parasite
density was quantiﬁed against 200 leucocytes on a thick
ﬁlm, assuming a total leukocyte count of 8000 per ll
(WHO, 1991). All slides were read by the ﬁrst laboratory
technician and then cross-checked by a laboratory super-
visor. A random sample of slides was sent to the African
Medical and Research Foundation (AMREF) for an
external quality control. Haemoglobin levels were meas-
ured using the Lovibond undiluted technique (Assistant
Co., Sondheim Rho ¨n, Germany). Blood samples for PCR
genotypic analysis were collected on Whatman N  3 ﬁlter
paper and analysed at the Kenya Medical Research
Institute according to a published method (Ranford-Cart-
wright et al. 1997). The three P. falciparum antigenic gene
loci of merozoite surface protein-1 (msp-1), merozoite
surface protein-2 (msp-2), and glutamate-rich protein
(GLURP) were used in differentiating recrudescence from
reinfection. The band proﬁles of paired pre-treatment and
failure-day samples were compared. Paired samples with
different band proﬁles were classiﬁed as reinfections,
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were similar. If the proﬁles were similar but there were
additional or missing bands in either sample, a recrudes-
cence was also concluded.
Data management and analysis
The sample size was calculated using a prevalence of
resistance of 50% for each drug. With a precision of 10%
and a type 1 error of 0.05, the sample size was 96 persons
for each drug. Allowing for a loss to follow-up of 20%, the
ﬁnal sample size was of 115 children in each treatment
group. Data were entered in a Microsoft Excel 2000
database. Each record was individually checked. Data were
analysed using SPSS 10.0.5 (SPSS Inc., Chicago, IL, USA)
and Epi-Info 6 (CDC, Atlanta, GA, USA). Failures were
expressed as proportions and corresponding 95% conﬁd-
ence intervals were calculated. Comparisons between
proportions were made using the v
2 test. Two-tailed
P-values <0.05 were considered signiﬁcant. Failures clas-
siﬁed as recrudescence after PCR analysis were conﬁrmed
as treatment failures, whereas when the PCR result showed
a reinfection, the patient was reclassiﬁed as an ATR.
Results
From 26 October 2001 to 28 January 2002, of 2010
children referred to the study clinic 1665 were excluded
(Figure 1). Main reasons for exclusions were (many were
excluded for more than one reason): negative malaria
smear (n ¼ 944), age not corresponding (n ¼ 688), mixed
parasitaemia (n ¼ 307), parasitaemia below 1000/ll
115 CQ
114 analysed 
D28
114 analysed 
D14
1 lost to follow-up 
115 SP
103 analysed 
D28
111 analysed 
D14
4 withdrawn 
8 no PCR result  
115 AQ
111 analysed 
D28
113 analysed 
D14
2 withdrawn 
2 no PCR result 
345 randomised 
2010 screened 
1665 exclusions
Figure 1 Details of study inclusions and follow-up.
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patients were randomized (115 in each study group), with
no statistically signiﬁcant differences in baseline charac-
teristics between the three groups (Table 1). After inclu-
sion, one patient was lost to follow-up (in the CQ group),
and six patients were subsequently excluded (four in the SP
group and two in the AQ group). Ten samples failed to
generate PCR results (eight in the SP group and two in the
AQ group) and were therefore excluded from the day 28
analysis.
Table 2 shows the therapeutic outcomes at days 14 and
28, before and after PCR adjustment. The vast majority of
late failures were asymptomatic: 74/77 (96%) in the CQ
group, 87/94 (92%) in the SP group and 86/92 (93%) in
the AQ group. At day 14, the proportion of failures was
89.5% in the CQ group, 54.0% in the SP group and 21.2%
in the AQ group. After PCR adjustment, the proportion of
failures at day 28 were 93.9% for CQ, 69.9% for SP and
25.2% for AQ. The proportion of failures was signiﬁcantly
higher in the CQ group than in the SP and the AQ groups
(P < 0.01 for each comparison) and signiﬁcantly higher in
the SP group than the AQ group (P < 0.01). The time of
occurrence of failures seemed correlated with the level of
drug resistance: before day 14 in 91.5% (98/107) of
failures in the CQ group, in 68.0% (49/72) in the SP group
and in 53.6% (15/28) in the AQ group. The external
quality control performed on 94 slides showed 97.8%
concordance.
Discussion
This study provides important missing data on the efﬁcacy
of CQ, SP and AQ for treatment of P. falciparum malaria
in southern Sudan, where data on antimalarial efﬁcacy are
scarce. The high failure rates to CQ (93.9%) and SP
(69.9%) are alarming, and conﬁrm the clinical observa-
tions of the local clinicians. The low efﬁcacy of CQ can be
explained by the frequent use of the drug within and
Table 1 Baseline characteristics of inclu-
ded patients Characteristic CQ (n ¼ 115) SP (n ¼ 115) AQ (n ¼ 115)
Age (months), mean (SD) 26.1 (16.4) 23.6 (15.2) 23.6 (15.1)
Gender ratio (male/female) 0.80 (51/64) 1.16 (62/53) 1.35 (66/49)
Axillary temperature ( C),
mean (SD)
37.4 (0.9) 37.5 (1.0) 37.4 (1.0)
Haemoglobin (g/dl) 10.5 10.4 10.1
Mean (SD) (1.5) (1.5) (1.5)
% <11 g/dl 59.1 66.1 68.7
Parasite density (/ll), 10 100 8850 11 765
geometric mean (range) (1040–98 256) (1000–96108) (1000–98 799)
Table 2 Therapeutic outcomes with and without PCR adjustment
No. % 95% CI No. % 95% CI No. % 95% CI
CQ (n ¼ 114) SP (n ¼ 111) AQ (n ¼ 113)
Before PCR adjustment
Treatment failure at D14 102 89.5 83.8–95.1 60 54.0 44.7–63.2 24 21.2 14.3–30.1
Treatment failure at D28 114 100 95.9–100 100 90.1 82.6–94.7 92 81.4 72.7–87.9
ETF 37 32.5 22.2–42 6 5.4 2.2–11.9 0 0 0–4.1
LTF D4–D14 65 57 47.4–66.1 54 48.6 39.1–58.3 24 21.2 14.3–30.1
LTF D15–D28 12 10.4 5.8–18 40 36 27.3–45.8 68 60.2 50.5–69.1
Adequate response 0 0 0–4.1 11 9.9 5.3–17.4 21 18.6 12.1–27.2
(n ¼ 103) (n ¼ 111)
After PCR adjustment
Treatment failure at D14 98 85.9 79.5–92.3 49 47.5 37.9–57.2 15 13.5 8.0–21.5
Treatment failure at D28 107 93.9 87.3–97.3 72 69.9 60.0–78.3 28 25.2 17.7–34.5
ETF 37 32.5 24.2–41.9 6 5.8 2.4–12.8 0 0 0–4.1
LTF D4–D14 61 53.6 43.9–62.8 43 41.7 32.2–51.9 15 13.5 8–21.5
LTF D15–D28 9 7.9 3.9–14.9 23 22.3 14.9–31.8 13 11.7 6.6–19.5
Adequate response 7 6.1 2.7–12.7 31 30.1 21.6–40.0 83 74.8 65.5–82.3
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was frequently observed, a factor that favours the propa-
gation of drug resistance (Wernsdorfer 1994). The low
efﬁcacy of the less prescribed SP corroborates the infor-
mation showing that resistance to SP is increasing in Africa
(White et al. 1999). The moderate failure rates to the not
previously used AQ can perhaps be attributed to cross-
resistance with CQ (Olliaro et al. 1996; Ochong et al.
2003), or perhaps to its inadequate use outside the ofﬁcial
health system. The difference in the proportion of rein-
fections between the three groups (AQ: 56%; SP: 19%;
CQ: 6%) may be explained by the level of drug resistance
to each of these drugs. Moreover, the much higher
proportion of reinfections in the AQ group compared with
the SP group could be explained by the prophylactic effect
of SP whose terminal elimination half-life is longer
(3–5 weeks) than that of AQ (1–3 weeks) (Krishna &
White 1996).
This information was collected through a 28-day
randomized study with PCR adjustment. This design
allowed the identiﬁcation of late failures occurring after
several weeks of follow-up, the adequate comparison
between the two study groups and the distinction of
recrudescences from reinfections (White 2002). The deﬁ-
nition of failure was based on parasitological criteria only.
This prevented us from distinguishing between parasito-
logical and clinical failures, which is currently recom-
mended by the WHO. Moreover, by giving rescue
treatment to these asymptomatic parasitaemic patients,
we were not able to identify patients who could eventu-
ally have cleared their parasitaemia spontaneously during
follow-up. In this sense, we think that our results may
over-estimate to some extent the level of drug failure.
They also need to be compared with some caution to
other studies performed in other areas of Sudan (National
Malaria Administration/Unicef 1999; Epicentre 2003; van
den Broek et al. 2003), considering the particular out-
come deﬁnition used in Kajo Keji.
The WHO recommends 25% as a threshold of thera-
peutic failure above which a change in therapy should be
implemented and adds that the process of looking for
alternative therapy should start even earlier when failure
rates reach 15–24% (Bloland et al. 1996; WHO 2001).
Even if our study measured parasitological failure, and not
clinical failure, on which the recommendations of WHO
are based, the ﬁndings of this study indicate that a change
in ﬁrst-line treatment is necessary. A long-term approach is
to consider combination therapy with an artemisinin
derivative. This is now being promoted as the best option
for treating P. falciparum malaria and retarding the
emergence of resistance (White & Olliaro 1996; WHO/
Roll Back Malaria 2003). The very high failure rates to CQ
and SP observed in Kajo Keji preclude them as partners in
such combination. The combination of artesunate with AQ
would certainly increase the antimalarial efﬁcacy com-
pared with AQ monotherapy, but with the available
information it is unclear whether acceptable cure rates
could be reached in Kajo Keji. Moreover, given the failure
rates of AQ found in our study, the useful therapeutic life
of this combination could be short.
Another option is the combination of artemether and
lumefantrine (Coartem ). Following this study, Coartem 
replaced CQ as ﬁrst-line treatment in Kajo Keji, after
discussions between MSF and the health authorities. Most
studies have shown that the six-dose regimen of this drug is
highly effective and well tolerated (von Seidlein et al. 1997;
van Vugt et al. 1998; Kshirsagar et al. 2000; Omari et al.
2003). However, this ﬁxed combination is expensive
(US$2.4/adult treatment), and adherence is likely to be
low, considering the need of taking the drug together with
a fatty meal. Monitoring and improving patient adherence
are integral to the introduction of Coartem , and showed
several months after introduction of the drug in Kajo Keji
that patient adherence was rather low (Depoortere et al.
2004). If we want to ensure treatment efﬁcacy in the years
to come, we need to ensure compliance with the regimen.
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